Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Phase 2

Withdrawn

Conditions: Metastatic Cancer
Colorectal Cancer

First Posted Date: 2009-07-10

Last Posted Date: 2022-08-30

Lead Sponsor: Federation Francophone de Cancerologie Digestive

Registration Number: NCT00936832

Locations: 🇫🇷
Hopital Ambroise Pare, Boulogne Billancourt, France

Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

Phase 1

Completed

Conditions: Colon Cancer With Metastases to the Liver

Interventions: Device: LC beads loaded with Irinotecan
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Bevacizumab

First Posted Date: 2009-07-03

Last Posted Date: 2021-06-11

Lead Sponsor: University of Louisville

Target Recruit Count: 70

Registration Number: NCT00932438

Locations: 🇺🇸
Northside Hospital/GA Cancer Specialists, Atlanta, Georgia, United States
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇺🇸
Clearview Cancer Center, Huntsville, Alabama, United States

and more 7 locations

SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: endocrine therapy
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Radiation: brachytherapy
Radiation: low-LET electron therapy
Drug: endocrine-modulating drug therapy
Radiation: low-LET photon therapy
Drug: fluorouracil
Drug: tamoxifen citrate
Radiation: radiation therapy

First Posted Date: 2009-06-29

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1558

Registration Number: NCT00929591

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)

Phase 2

Completed

Conditions: Stage II Lymphoepithelioma of the Nasopharynx
Stage III Lymphoepithelioma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage IV Lymphoepithelioma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage II Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: carboplatin
Drug: fluorouracil
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy

First Posted Date: 2009-05-11

Last Posted Date: 2021-04-06

Lead Sponsor: Stanford University

Target Recruit Count: 26

Registration Number: NCT00896181

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms

Interventions: Drug: Placebo
Drug: Sorafenib
Drug: Oxaliplatin or Irinotecan
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2009-04-28

Last Posted Date: 2013-03-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 101

Registration Number: NCT00889343

Locations: 🇩🇪
Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie, Neumünster, Schleswig-Holstein, Germany
🇩🇪
Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt, Neunkirchen, Saarland, Germany
🇩🇪
Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum, Pforzheim, Baden-Würtemberg, Germany

and more 53 locations

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

Phase 2

Conditions: Chemotherapeutic Agent Toxicity
Colorectal Cancer
Neurotoxicity

First Posted Date: 2009-04-21

Last Posted Date: 2009-07-08

Lead Sponsor: Institut Cancerologie de l'Ouest

Target Recruit Count: 206

Registration Number: NCT00884767

Locations: 🇫🇷
Centre Paul Papin, Angers, France

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Phase 1

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: FOLFOX regimen
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Drug: ursodiol
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Genetic: western blotting
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: positron emission tomography (PET)

First Posted Date: 2009-04-01

Last Posted Date: 2024-12-04

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 11

Registration Number: NCT00873275

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: docetaxel
Drug: epirubicin hydrochloride
Drug: fluorouracil
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: hypofractionated radiation therapy
Radiation: image-guided radiation therapy
Radiation: radiation therapy
Radiation: stereotactic radiosurgery

First Posted Date: 2009-03-31

Last Posted Date: 2015-02-10

Lead Sponsor: Centre Antoine Lacassagne

Target Recruit Count: 26

Registration Number: NCT00872625

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-fluorouracil
Radiation: Preoperative Radiotherapy
Procedure: Surgery

First Posted Date: 2009-03-19

Last Posted Date: 2017-08-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT00865189

Locations: 🇫🇷
ICO Paul Papin; Oncologie Medicale., Angers, France
🇫🇷
HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
🇫🇷
Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France

and more 17 locations

A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Carcinoma

Interventions: Biological: IMC-1121B (ramucirumab)
Drug: Oxaliplatin
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2009-03-17

Last Posted Date: 2014-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT00862784

Locations: 🇪🇸
ImClone Investigational Site, Valencia, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy